Answers are grounded in this paper and cite their sources.
We have provided evidence for a multifaceted antitumor-function of the Toll-like receptor 7 (TLR7) agonist imiquimod, which rapidly recruits plasmacytoid dendritic cells and possibly other immune cells into tumors by inducing the secretion of CCL2 by dermal cells. Imiquimod induces pDC maturation and their conversion into cytolytic killer cells, which are capable of eliminating tumors independently from the adaptive immune system.
No takes yet. Share an insight, caveat, or question.
Holcmann et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: